SOURCE: AMI Research

AMI Research

February 08, 2012 11:30 ET

AMI Research Initiates Analyst Coverage On China Kangtai Cactus Biotech; BUY

NEW YORK, NY--(Marketwire - Feb 8, 2012) - AMI Research, ( a leading provider of equity research reports and a division of IR Firm, Hawk Associates Inc., announced today that it has initiated equity research coverage on China Kangtai Cactus Biotech, Inc. (OTCBB: CKGT).

AMI president Peter J. D'Agostino said, "Cactus Kangtai is poised for substantial growth through its broad portfolio of nutritional products. CKGT has successfully increased its cactus products market share to 60%, and in our opinion will continue to do so with the recent launch of its cigarette product. We project strong top-line growth with solid margins through 2013. CKGT is a value-play in our opinion and has been hindered by poor investor sentiment, which has plagued many Chinese companies."

AMI Research provides an institutional-quality, equity research initiation report detailing China Kangtai Cactus' key statistics, management, growth catalysts, financial outlook and valuation. The complete 7-page report is available to download for free at the AMI Research website,

About China Kangtai Cactus Biotech
Headquartered in Harbin, Heilongjiang Province China, China Kangtai Cactus Biotech Inc. (OTCBB: CKGT) is China's leading cactus grower and producer of cactus related products including nutraceuticals, wine, liquor extracts and powders, nutritional food, livestock feed, fish feed and cigarettes. The company has 14 product lines. For additional information about China Kangtai Cactus Biotech, visit

About AMI Research
AMI Research is a wholly owned subsidiary of Hawk Associates and provides fundamental business analysis for promising companies that do not have traditional Wall Street analyst coverage. AMI Research creates comprehensive and quality equity research reports for small cap and microcap companies that need to reach investors. These detailed reports provide retail, individual and institutional investors with an in-depth understanding of a company's intrinsic value and its technology. The AMI equity research reports detail the company's industry, strategic position, core business model, financial history and future growth catalysts. Please visit

AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI). The cost of a one-year continuing research program is $16,000 prepaid for four research reports. AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst's compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report.

For more information, contact Peter J. D'Agostino, president at 212.541.2465, email to: or visit

Contact Information